Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study

医学 肝细胞癌 倾向得分匹配 内科学 胃肠病学 阶段(地层学) 回顾性队列研究 总体生存率 队列 完全响应 肝癌 存活率 肝切除术 外科 切除术 化疗 生物 古生物学
作者
Zili Hu,Xiaohui Wang,Yizhen Fu,Dinghua Yang,Zhongguo Zhou,Minshan Chen,Xin Song,Yaojun Zhang
出处
期刊:International Journal of Surgery [Wolters Kluwer]
卷期号:110 (2): 1019-1027 被引量:3
标识
DOI:10.1097/js9.0000000000000942
摘要

Background: High rate of tumor recurrence jeopardized the long-term survival of hepatocellular carcinoma (HCC) patients with complete response to transarterial chemoembolization (TACE). This study aims to evaluate the survival benefit of liver resection (LR) following the complete response to TACE for intermediate-stage HCC. Methods: A total of 281 intermediate-stage HCC patients with complete response to TACE followed by persistent observation (TACE group) or LR (TLR group) from 01 January 2011 to 31 December 2021 from three institutions in China were included. Overall survival (OS) and disease-free survival (DFS) of patients were compared between the two groups by propensity score–matching (PSM). Results: After PSM, the 1-year, 3-year, and 5-year OS rates were 91.4, 71.5, and 57.1% in the TACE group, and 96.6, 81.8, and 72.1% in the TLR group. The 1-year, 3-year, and 5-year DFS rates were 50.6, 22.6, and 6.8% in the TACE group, and 77.3, 56.3, and 38.7% in the TLR group. Compared with the TACE group, the TLR group showed significantly longer OS (HR, 0.528; 95% CI: 0.315–0.887; P =0.014) and DFS (HR, 0.388; 95% CI: 0.260–0.580; P <0.001). In patients beyond up-to-seven criterion, no difference was observed with OS (HR, 0.708; 95% CI: 0.354–1.419; P =0.329). LR following the complete response to TACE was safety. Conclusions: This study suggests that intermediate-stage HCC patients could benefit from LR following the complete response to TACE, resulting in longer OS and DFS. In addition, patients beyond up-to-seven could not benefit from the LR treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小曾应助Florencia采纳,获得10
刚刚
神外王001完成签到 ,获得积分10
刚刚
5秒前
你是谁完成签到,获得积分10
6秒前
majf完成签到,获得积分10
7秒前
linhanwenzhou完成签到,获得积分10
7秒前
JSY关注了科研通微信公众号
7秒前
853225598完成签到,获得积分10
7秒前
798完成签到,获得积分10
8秒前
善学以致用应助董怼怼采纳,获得10
8秒前
妍儿完成签到,获得积分20
9秒前
隐形曼青应助高大的水壶采纳,获得10
9秒前
马哥二弟无敌完成签到 ,获得积分10
10秒前
11秒前
Florencia完成签到,获得积分10
11秒前
务实颜完成签到 ,获得积分10
11秒前
11秒前
amberzyc应助小远采纳,获得10
12秒前
12秒前
13秒前
13秒前
14秒前
14秒前
Rondab应助小猪采纳,获得30
14秒前
DLDL完成签到,获得积分10
14秒前
15秒前
沧海云完成签到 ,获得积分10
15秒前
发嗲的迎天完成签到 ,获得积分10
16秒前
hahaha发布了新的文献求助10
17秒前
小马甲应助zx0914采纳,获得10
17秒前
阳光保温杯完成签到 ,获得积分10
17秒前
微冷潇一应助mo采纳,获得10
18秒前
顺心凝天完成签到,获得积分10
18秒前
yishiqi10086发布了新的文献求助10
19秒前
何相逢应助科研通管家采纳,获得10
20秒前
20秒前
CipherSage应助科研通管家采纳,获得10
20秒前
予修应助科研通管家采纳,获得10
20秒前
20秒前
czj完成签到,获得积分0
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029